List of Excipients in Branded Drug TOLTERODINE TARTRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	TOLTERODINE TARTRATE	tolterodine tartrate	59762-0170	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	TOLTERODINE TARTRATE	tolterodine tartrate	59762-0170	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Mylan Pharmaceuticals Inc	TOLTERODINE TARTRATE	tolterodine tartrate	59762-0170	HYPROMELLOSE
Mylan Pharmaceuticals Inc	TOLTERODINE TARTRATE	tolterodine tartrate	59762-0170	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	TOLTERODINE TARTRATE	tolterodine tartrate	59762-0170	SILICON DIOXIDE

Generic Drugs Containing TOLTERODINE TARTRATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	tolterodine tartrate	0093-0010	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	tolterodine tartrate	0093-0010	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	tolterodine tartrate	0093-0010	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	tolterodine tartrate	0093-0010	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	tolterodine tartrate	0093-0010	POLYETHYLENE GLYCOL 6000

What are the Most Frequently-Used Excipients in TOLTERODINE TARTRATE?

# Of NDCs	Excipient
1	ALCOHOL
3	AMMONIA
1	BUTYL ALCOHOL
3	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
1	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE

Tolterodine Tartrate Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Tolterodine tartrate is a mature oral antimuscarinic used for overactive bladder and urinary urgency. Its commercial opportunity is no longer based on active-ingredient exclusivity. The strongest opportunities are in differentiated extended-release delivery, improved tolerability, pediatric or geriatric usability, preservative-free liquid systems, fixed-dose combinations, and cost-efficient generic manufacturing.

The market is dominated by generic tolterodine tartrate tablets and extended-release capsules. Detrol and Detrol LA established the original commercial formulations, but the relevant U.S. patent and regulatory exclusivity periods have expired. A new entrant would need to compete on price, supply reliability, dosage-form convenience, bioequivalence execution, or a clinically meaningful reduction in anticholinergic burden.

What is tolterodine tartrate and how is it marketed?

Tolterodine tartrate is the tartrate salt of tolterodine, a competitive muscarinic receptor antagonist. It is administered orally for overactive bladder symptoms, including urinary frequency, urgency, and urge urinary incontinence.

Attribute	Tolterodine tartrate
Active ingredient	Tolterodine tartrate
Therapeutic class	Antimuscarinic urinary antispasmodic
Original brand	Detrol
Extended-release brand	Detrol LA
Immediate-release strengths	1 mg and 2 mg tablets
Extended-release strengths	2 mg and 4 mg capsules
Original U.S. approval	Detrol, 1998
Extended-release U.S. approval	Detrol LA, 2000
Primary indication	Overactive bladder
Regulatory category	Small-molecule prescription drug
Biosimilar exposure	None
Current commercial position	Mature generic market

The FDA label identifies tolterodine tartrate as the active pharmaceutical ingredient in Detrol tablets and Detrol LA extended-release capsules. The extended-release product uses a multiparticulate delivery system rather than a conventional immediate-release tablet matrix (FDA, 2016a; FDA, 2016b).

What patents protect tolterodine tartrate and Detrol LA?

The original commercial patent estate covered tolterodine, pharmaceutical compositions, therapeutic use, and extended-release delivery. Those rights are no longer the primary barrier to U.S. generic entry.

Core composition and use patents

The early estate included patents covering:

• Tolterodine chemical composition.
• Tolterodine salts, including tartrate.
• Treatment of urinary urgency and incontinence.
• Immediate-release oral dosage forms.
• Extended-release oral delivery.
• Multiparticulate capsule systems.

The most commercially relevant patents were associated with Pharmacia, later integrated into Pfizer's pharmaceutical portfolio. The original Detrol product received U.S. approval in 1998, while Detrol LA was approved in 2000. The patent term and any patent-term extension attached to the original products have expired, allowing broad generic competition.

A current patent review should rely on the FDA Orange Book and the USPTO Patent Center because Orange Book listings and litigation positions can change. The strategic conclusion is stable: tolterodine tartrate does not have an active, product-defining U.S. exclusivity position comparable to a newly approved branded drug (FDA, n.d.-a).

What is the Orange Book status of tolterodine tartrate?

The Orange Book historically listed Detrol and Detrol LA patents and associated exclusivity information. The market now includes approved generic immediate-release tablets and extended-release capsules. The relevant Orange Book value is therefore not residual brand protection but the reference-listed-drug framework used for abbreviated new drug applications.

An applicant developing a new tolterodine product should review:

1. Current reference-listed-drug designation.
2. Listed patents for Detrol and Detrol LA.
3. Whether any listed patent remains unexpired.
4. Approved strengths and dosage forms.
5. Therapeutic-equivalence codes for generic products.
6. Any pediatric exclusivity or regulatory exclusivity entries.

When did tolterodine lose exclusivity?

Tolterodine's core U.S. exclusivity was lost after expiration of the original composition, use, and formulation patent estate. Generic approvals followed for immediate-release tablets and extended-release capsules.

Milestone	Commercial effect
1998 Detrol approval	Established immediate-release branded market
2000 Detrol LA approval	Created extended-release franchise
Patent-term expiry	Opened the market to generic development
Generic tablet approvals	Compressed immediate-release pricing
Generic extended-release approvals	Reduced the remaining formulation premium
Current market	Mature, price-sensitive generic category

The commercial life cycle resembles other mature antimuscarinic products: branded revenue was concentrated during the period of patent protection, followed by rapid price erosion after generic entry. Pfizer reported Detrol as a major product during its peak commercial period, with annual sales exceeding $1 billion before generic competition materially reduced the franchise value (Pfizer, 2005).

What excipients are used in tolterodine tartrate formulations?

Excipient selection depends on whether the target product is an immediate-release tablet, extended-release multiparticulate capsule, orally disintegrating product, or liquid formulation.

Immediate-release tablets

The Detrol immediate-release tablet uses conventional solid-dose excipients. The label identifies excipient classes including lactose, microcrystalline cellulose or cellulose-based fillers, colloidal silicon dioxide, and stearic acid or related lubricating components, depending on the product presentation and manufacturer (FDA, 2016a).

A generic immediate-release formulation generally requires:

• A diluent to achieve tablet weight and content uniformity.
• A dry binder to support compactability.
• A disintegrant for rapid drug release.
• A glidant to improve powder flow.
• A lubricant to prevent sticking and ejection defects.
• A film-coating system for appearance, identification, and moisture protection.

Because the dose is low, content uniformity is a central development issue. Tolterodine tartrate loading may be small relative to tablet mass, increasing the importance of ordered mixing, geometric dilution, segregation control, and blend-hold validation.

Extended-release capsules

Detrol LA uses extended-release beads or pellets filled into hard gelatin capsules. This architecture creates a more defensible formulation platform than a standard tablet because release depends on particle size, coating thickness, polymer permeability, drug loading, and capsule fill uniformity.

Typical excipient categories include:

Functional layer	Common excipient category	Development purpose
Starter core	Sugar spheres or inert pellets	Provides a uniform substrate
Drug layer	Binder and wetting system	Applies tolterodine tartrate to the core
Release-control layer	Ethylcellulose or other water-insoluble polymer	Controls diffusion
Pore-forming layer	Hydrophilic polymer or soluble excipient	Adjusts release rate
Capsule shell	Gelatin or hypromellose	Encapsulates multiparticulates
Process aids	Talc, silica, antistatic agents	Improve coating and handling

The formulation target is once-daily delivery with a controlled plasma profile. The formulation must avoid dose dumping under altered pH, agitation, alcohol exposure, or food conditions. Multiparticulate systems can reduce the consequences of a single-unit coating defect, but they create manufacturing complexity.

Alternative excipient platforms

Potential platforms include:

• Hypromellose matrix tablets.
• Ethylcellulose-coated pellets.
• Ammonio methacrylate copolymer systems.
• Lipid or wax matrices.
• Orally disintegrating tablets.
• Taste-masked granules.
• Aqueous oral suspensions.
• Sprinkle capsules containing coated beads.
• Low-moisture direct-compression tablets.

A reformulator should not assume that an excipient change is commercially meaningful by itself. The change must produce a measurable benefit, such as lower variability, better swallowability, improved stability, lower manufacturing cost, or a new administration route.

What formulation patents could protect a new tolterodine product?

The strongest new patent positions would focus on formulation performance rather than tolterodine itself.

Extended-release formulation patents

Potential claim categories include:

• Specific pellet size distributions.
• Defined polymer-to-drug ratios.
• Multi-layer coating structures.
• Controlled release across gastric and intestinal pH.
• Reduced alcohol-induced dose dumping.
• Specific dissolution profiles.
• Reduced food-effect variability.
• Capsule sprinkle formulations.
• Manufacturing processes that improve coating uniformity.

A patent directed only to conventional use of ethylcellulose or hypromellose is likely to face substantial validity and obviousness risk. Stronger claims would link composition to a defined dissolution profile, pharmacokinetic result, or manufacturing advantage.

Orally disintegrating and pediatric formulations

Tolterodine has a low dose, which supports compact orally disintegrating dosage forms. The main formulation problems are taste, dose uniformity, moisture sensitivity, and disintegration without excessive friability.

Commercially relevant patent claims could cover:

• Taste-masked tolterodine particles.
• Specific ion-exchange resin complexes.
• Low-hygroscopicity granules.
• Fast-disintegrating tablets with defined mechanical strength.
• Unit-dose sachets or oral films.
• Pediatric dosage flexibility.

A pediatric or geriatric product would need a clear clinical and adherence rationale. A different tablet shape or flavor alone would offer limited protection.

Liquid formulations

An oral solution or suspension could address patients who cannot swallow tablets or capsules. Tolterodine's physicochemical properties create challenges in aqueous systems, including solubility, pH control, precipitation, taste, and chemical stability.

Possible formulation strategies include:

• pH-adjusted aqueous solution.
• Suspension using a structured vehicle.
• Cyclodextrin complexation.
• Surfactant-assisted solubilization.
• Taste masking with polymeric coating.
• Unit-dose preservative-free packaging.
• Powder for reconstitution.

Liquid products may support a 505(b)(2) strategy if the product introduces a new dosage form, administration method, or patient population. The regulatory and commercial value would depend on clinical differentiation and payer acceptance.

How should companies select excipients for tolterodine tartrate?

Excipient selection should follow the intended product strategy.

Commercial goal	Preferred formulation direction	Key excipient priorities
Lowest-cost generic tablet	Immediate-release tablet	Commodity fillers, robust disintegration, high-throughput compression
Once-daily generic	Multiparticulate capsule or matrix tablet	Reproducible release, coating efficiency, alcohol resistance
Geriatric adherence	ODT or sprinkle capsule	Taste masking, low friability, easy administration
Pediatric use	Liquid, ODT, or flexible-dose granules	Palatability, dose flexibility, preservative control
Premium differentiated product	New release profile or delivery system	Clinical performance, patentable structure, stability
Manufacturing efficiency	Direct compression or simplified coating	Low process complexity, low waste, broad supplier base
Supply-chain resilience	Multi-source excipient platform	Pharmacopoeial grade, global availability, low regulatory risk

A generic manufacturer should favor widely available excipients with established compendial status. Novel excipients can increase regulatory burden, supplier dependence, and comparability work. The exception is a reformulated product where a novel excipient is necessary to achieve a clinically relevant delivery benefit.

What generic entry risks exist for tolterodine tartrate?

The immediate-release market has high generic substitution and limited pricing power. The extended-release market has greater technical risk because bioequivalence depends on the complete release profile rather than only the active ingredient.

Immediate-release risks

Key risks include:

• Low-dose content-uniformity failures.
• Dissolution variability.
• Tablet hardness and disintegration conflicts.
• Lactose or excipient compatibility.
• Batch-to-batch blend segregation.
• Limited margin after distributor and pharmacy discounts.

Extended-release risks

Key risks include:

• Failure to match the reference dissolution profile.
• Inconsistent pellet coating thickness.
• Premature release during alcohol exposure.
• Food-effect differences.
• Capsule fill-weight variation.
• In vitro-in vivo correlation failure.
• High capital cost for fluid-bed coating equipment.

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. Formulation changes that alter release behavior can trigger additional development and regulatory work (FDA, 2022).

Which companies are challenging the Detrol franchise?

Tolterodine is challenged primarily by generic manufacturers rather than by a single branded patent challenger. U.S. generic suppliers have entered the market with immediate-release tablets and extended-release capsules. The competitive field typically includes large generic companies, regional suppliers, and authorized or contract manufacturers.

The relevant competitive groups are:

1. High-volume generic suppliers competing on unit cost.
2. Specialized modified-release manufacturers with multiparticulate capabilities.
3. Contract development and manufacturing organizations offering pellet coating.
4. Branded overactive-bladder competitors, including oxybutynin, solifenacin, fesoterodine, darifenacin, and trospium.
5. Beta-3 agonist products, including mirabegron and vibegron, which compete on mechanism and tolerability.

The most direct commercial threat to a new tolterodine product is not patent litigation. It is price compression and substitution by established generic suppliers.

How does tolterodine compare with competing overactive-bladder drugs?

Product	Mechanism	Generic position	Commercial implication
Tolterodine	Muscarinic antagonist	Mature generic	Low acquisition cost, limited differentiation
Oxybutynin	Muscarinic antagonist	Mature generic	Strong price competition; multiple dosage forms
Solifenacin	Muscarinic antagonist	Generic available	Competes on dosing and tolerability
Trospium	Muscarinic antagonist	Generic available	Differentiated pharmacokinetic positioning
Fesoterodine	Muscarinic antagonist	More limited generic dynamics	Extended-release competition
Mirabegron	Beta-3 agonist	Branded and generic-transition dynamics vary by market	Competes on non-anticholinergic mechanism
Vibegron	Beta-3 agonist	Branded	Premium positioning and anticholinergic avoidance

Tolterodine's principal disadvantage is class-related anticholinergic tolerability, including dry mouth, constipation, and potential cognitive concerns in vulnerable patients. A new formulation that improves adherence without changing systemic exposure may have limited value unless it also supports a distinct regulatory or reimbursement position.

What licensing deals and manufacturing opportunities exist?

The original commercial rights were associated with Pharmacia and later Pfizer. The current opportunity is more likely to involve formulation licensing, regional commercialization, or contract manufacturing than acquisition of a valuable core patent estate.

Licensing opportunities

Potential deal structures include:

• Regional rights to generic extended-release capsules.
• 505(b)(2) rights for oral liquid or orally disintegrating products.
• Technology licensing for coated multiparticulates.
• Co-development with a specialty urology company.
• In-licensing of a taste-masking platform.
• Private-label supply for pharmacy or hospital channels.

A licensing target should have at least one defensible asset: regulatory approval, validated bioequivalence, reliable supply, a differentiated dosage form, or a patent covering a clinically relevant formulation.

Manufacturing and IP barriers

The main manufacturing barriers are process-based:

• Fluid-bed coating capability.
• Tight control of pellet size and coating weight.
• Low-dose blend uniformity.
• Stability under moisture and heat.
• Capsule filling of multiparticulates.
• Dissolution testing across multiple media.
• Scale-up without altering release kinetics.

Process patents can protect coating sequences, curing conditions, polymer ratios, and in-process controls. Trade secrets may be more valuable than patents where the advantage is a narrow operating window or high-yield coating process.

What is the FDA regulatory pathway for new tolterodine products?

A conventional immediate-release generic generally proceeds through an ANDA referencing the relevant listed drug. A modified-release product may also use the ANDA pathway if it meets the applicable reference-product and bioequivalence requirements.

A 505(b)(2) application may be appropriate for:

• A new oral liquid.
• A new route or administration device.
• A clinically differentiated release profile.
• A new patient population.
• A product with sufficient reliance on existing tolterodine safety and efficacy data.

FDA approval requires attention to dosage-form equivalence, inactive ingredients, labeling, dissolution, stability, and bioequivalence. For extended-release products, the development program should treat formulation composition and manufacturing process as one integrated control system.

How strong is the current tolterodine patent estate?

The legacy estate is commercially weak because the core patents have expired and generic substitution is established. A new estate could be moderately strong if it protects a specific delivery architecture with demonstrated clinical or pharmacokinetic advantages.

Asset type	Relative strength
Tolterodine tartrate composition patent	Expired or commercially unavailable as a barrier
Conventional immediate-release tablet	Weak unless process cost is unusually low
Standard extended-release matrix	Moderate to weak
Multiparticulate extended-release system	Moderate if claims are technically narrow and validated
Taste-masked pediatric formulation	Moderate to strong if clinically differentiated
Preservative-free liquid	Moderate, dependent on stability and usability data
Manufacturing process patent	Moderate; vulnerable to design-around
Trade secret coating process	Potentially strong but difficult to enforce
New combination product	Potentially strong if clinically and legally distinct

What commercial opportunities remain for tolterodine tartrate?

The most credible opportunities are:

1. Low-cost, reliable generic supply in markets with limited competition.
2. Extended-release capsules manufactured through efficient pellet coating.
3. Sprinkle capsules for patients with swallowing difficulty.
4. Orally disintegrating tablets for adherence-focused channels.
5. Pediatric or geriatric liquid formulations.
6. Regional licensing in countries where branded access remains limited.
7. Combination products pairing tolterodine with another urologic therapy.
8. Contract manufacturing of multiparticulate dosage forms.
9. Private-label supply for institutional purchasers.
10. Reformulation aimed at reducing alcohol-related release variability.

The strongest near-term business case is a cost-efficient generic extended-release product supported by robust manufacturing. The strongest longer-term intellectual-property case is a patient-centered dosage form with a defensible delivery mechanism and a credible 505(b)(2) rationale.

Key Takeaways

• Tolterodine tartrate is a mature small-molecule product with no biosimilar risk.
• Detrol and Detrol LA patent-based exclusivity has ended, and generic competition is established.
• Immediate-release tablets are commodity products with limited margin and weak formulation differentiation.
• Extended-release multiparticulates offer the largest technical and manufacturing opportunity.
• Excipient strategy should prioritize low-dose uniformity, controlled dissolution, stability, and supplier resilience.
• Pediatric liquids, orally disintegrating tablets, and sprinkle capsules are the most credible differentiated dosage forms.
• A new formulation patent should claim a specific composition linked to release, pharmacokinetic, stability, or usability performance.
• The main commercial threat is price erosion, not active patent litigation.
• Licensing value is concentrated in regulatory approvals, manufacturing know-how, and differentiated delivery platforms.
• A conventional generic is best suited to an ANDA; a materially new dosage form may support a 505(b)(2) strategy.

FAQs About Tolterodine Tartrate Excipient and Commercial Strategy

Can lactose be used in tolterodine tartrate tablets?

Yes. Lactose is used in legacy tablet formulations and can function as a diluent. Compatibility, moisture exposure, patient labeling, and supplier consistency must be assessed during development.

Is tolterodine tartrate suitable for an orally disintegrating tablet?

Yes. The low dose supports an orally disintegrating tablet, but taste masking, content uniformity, friability, and moisture protection are central development requirements.

What is the best extended-release technology for tolterodine?

Multiparticulate pellets are commercially attractive because polymer-coated particles can provide reproducible once-daily release. A matrix tablet may reduce manufacturing cost but can be harder to optimize across dose strengths and physiological conditions.

Can a new tolterodine liquid obtain market exclusivity?

A new liquid may support a 505(b)(2) application and formulation patent protection if it provides a distinct dosage form, stability profile, administration benefit, or patient-use advantage. The regulatory and commercial value depends on the specific product claims.

Does tolterodine tartrate require a novel excipient for differentiation?

No. Existing excipients can support meaningful differentiation through taste masking, controlled release, preservative-free packaging, improved stability, or improved manufacturing performance. Novel excipients are not necessary and may increase regulatory complexity.

References

1. European Medicines Agency. (2023). Detrol and tolterodine product information. EMA.

2. Food and Drug Administration. (2016a). Detrol (tolterodine tartrate) tablets: Prescribing information. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2016b). Detrol LA (tolterodine tartrate extended release capsules): Prescribing information. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2022). Abbreviated new drug application submissions: Generic drug development guidance. U.S. Department of Health and Human Services.

5. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

6. Food and Drug Administration. (n.d.-b). Inactive ingredient database. U.S. Department of Health and Human Services.

7. Pfizer Inc. (2005). Annual report 2004. Pfizer Inc.